Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

June 6, 2011

RXi Claims Positive Breast Cancer Trial Results

Worcester-based RXi Pharmaceuticals Corp. announced results of a Phase 2 study of its NeuVax breast cancer vaccine that it said demonstrate the therapy's promise.

NeuVax was developed by Arizona-based biotechnology firm Apthera Inc., which RXi acquired in April.

RXi said the trials enrolled 182 patients who received the vaccine once a month for six months, and then got booster shots every six months.

At 36 months, the treated groups showed no recurrences of cancer, compared to a 22-percent recurrence rate in a control group.

RXi said it plans to begin a Phase 3 trial of the vaccine in the first half of 2012.

Sign up for Enews

WBJ Web Partners

Most Recent

Most Recent

0 Comments

Order a PDF